Senior Deals Analyst, Biomedtracker
Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont..
Latest From Deanna Kamienski
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.
During Q2, biopharma merger and acquisition deal value reached $29bn and drew in $36.8bn in potential deal value from alliances. Device company M&A values reached $988m, while in vitro diagnostics and research tools players’ M&A activity totaled $450m.
During Q2, biopharmas brought in an aggregate $23.8bn in financing and device company fundraising totaled $2.4bn; while in vitro diagnostic firms and research tools players raised $684m.
Three $1bn+ alliances were penned in June. Topping the list was a potential $2.5bn deal under which Bausch & Lomb acquired Novartis’ Xiidra (lifitegrast ophthalmic solution) for signs and symptoms of dry eye disease; investigational compounds SAF312 (libvatrep) for chronic ocular surface pain and OJL332 for an undisclosed ophthalmic indication; plus rights to use the AcuStream delivery device in dry eye indications.
Four $1bn+ alliances were penned in May. Topping the list was a potential $2bn deal between Bliss Biopharmaceutical and Eisai for BB-1701, which is currently in Phase I/II studies in the US and China for various types of cancers. Both parties will conduct co-development activities related to BB-1701 through an option period. Should Eisai exercise its option, it would receive worldwide rights (excluding Greater China) to develop and commercialize BB-1701.
During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.